Cargando…

A 15-Year Study on Up(4)A in Cardiovascular Disease

Detalles Bibliográficos
Autores principales:	Zhou, Zhichao, Matsumoto, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417886/ https://www.ncbi.nlm.nih.gov/pubmed/32848797 http://dx.doi.org/10.3389/fphar.2020.01200

Ejemplares similares

P2X7 Receptor–Mediated Inflammation in Cardiovascular Disease
por: Zhou, Junteng, et al.
Publicado: (2021)

Are Anticholinergic Medications Associated With Increased Risk of Dementia and Behavioral and Psychological Symptoms of Dementia? A Nationwide 15-Year Follow-Up Cohort Study in Taiwan
por: Liu, Yia-Ping, et al.
Publicado: (2020)

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
por: Mela, Aneta, et al.
Publicado: (2020)

RNA Methylations in Cardiovascular Diseases, Molecular Structure, Biological Functions and Regulatory Roles in Cardiovascular Diseases
por: Zhou, Wanwan, et al.
Publicado: (2021)

Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate
por: Park, Jeewon, et al.
Publicado: (2020)

Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases
por: Zhou, Yan-Xi, et al.
Publicado: (2021)

Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study
por: Wagner, Daniel, et al.
Publicado: (2015)

Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison
por: Loussouarn, Gildas, et al.
Publicado: (2016)

Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study
por: Liao, Kuan-Fu, et al.
Publicado: (2017)

Risk for Cardiovascular Disease and One-Year Mortality in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Syndrome Overlap Syndrome
por: Tang, Manyun, et al.
Publicado: (2021)

The Role of Necroptosis in Cardiovascular Disease
por: Zhe-Wei, Shi, et al.
Publicado: (2018)

Trends and characteristics of COVID-19 and cardiovascular disease related studies
por: Cheng, Ao, et al.
Publicado: (2023)

Regulatory Mechanisms of Baicalin in Cardiovascular Diseases: A Review
por: Xin, Laiyun, et al.
Publicado: (2020)

Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review
por: Gao, Jialiang, et al.
Publicado: (2017)

A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
por: Cai, Yun, et al.
Publicado: (2021)

Smoking, Blood Pressure, and Cardiovascular Disease Mortality in a Large Cohort of Chinese Men with 15 Years Follow-up
por: Tan, Jibin, et al.
Publicado: (2018)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
por: Song, Yun-Kyoung, et al.
Publicado: (2023)

Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease
por: Zhang, Zhongwen, et al.
Publicado: (2020)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023)

Inside epoxyeicosatrienoic acids and cardiovascular disease
por: Tacconelli, Stefania, et al.
Publicado: (2014)

The Emerging Role of Ferroptosis in Cardiovascular Diseases
por: Hong, Min, et al.
Publicado: (2022)

The Role of CXC Chemokines in Cardiovascular Diseases
por: Lu, Xiyi, et al.
Publicado: (2022)

The role of immune checkpoints in cardiovascular disease
por: Yousif, Laura I., et al.
Publicado: (2022)

Editorial: Emerging mechanisms in cardiovascular disease
por: Yalcin, Huseyin C., et al.
Publicado: (2023)

Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study
por: Tsai, Wen-Hsuan, et al.
Publicado: (2023)

Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming
por: Chen, Hao, et al.
Publicado: (2023)

A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
por: Fang, Lu, et al.
Publicado: (2017)

Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
por: Xu, Mengda, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

Endoplasmic reticulum as a target in cardiovascular diseases: Is there a role for flavonoids?
por: Keylani, Kimia, et al.
Publicado: (2023)

Editorial: Efficacy and mechanism of herbal medicines and their functional compounds in preventing and treating cardiovascular diseases and cardiovascular disease risk factors
por: Meng, Tiantian, et al.
Publicado: (2023)

Targets of Vitamin C With Therapeutic Potential for Cardiovascular Disease and Underlying Mechanisms: A Study of Network Pharmacology
por: Zhu, Ning, et al.
Publicado: (2021)

Regulation of CaMKII signaling in cardiovascular disease
por: Mollova, Mariya Y., et al.
Publicado: (2015)

Natural AMPK Activators in Cardiovascular Disease Prevention
por: Heidary Moghaddam, Reza, et al.
Publicado: (2022)

Editorial: Adipose Tissue in the Cardiovascular Homeostasis and Disease
por: Butcher, Joshua T., et al.
Publicado: (2021)

Effect of Traditional Chinese Medicine on the Cardiovascular Diseases
por: Jiang, Yang, et al.
Publicado: (2022)

Promising Antioxidative Effect of Berberine in Cardiovascular Diseases
por: An, Na, et al.
Publicado: (2022)

Emodin in cardiovascular disease: The role and therapeutic potential
por: Guo, Yuanyuan, et al.
Publicado: (2022)

Editorial: Circadian biology, cardiovascular function and disease
por: Chong, Nelson, et al.
Publicado: (2023)

Insights into bone morphogenetic proteins in cardiovascular diseases
por: Ye, Di, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1n0fq7ghhk644f74catob9jsii